Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet K Coller

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Pharmacology & Therapeutics|February 10, 2012
Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependenceJanet K Coller, Mark R Hutchinson
European Journal of Clinical Pharmacology|October 30, 2008
Role of active metabolites in the use of opioidsJanet K Coller, Lona L Christrup, Andrew A Somogyi
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 4, 2006
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatmentsDaniel T Barratt, Janet K Coller, Andrew A Somogyi
Clinical Pharmacology and Therapeutics|March 7, 2007
Pharmacogenetics of opioidsAndrew A Somogyi, Daniel T Barratt, Janet K Coller
Journal of Cellular Physiology|July 31, 2020
Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory diseaseElise E Bruning, Janet K Coller, Hannah R Wardill, et al.
Clinical Nutrition ESPEN|July 17, 2024
Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical dataIfeoma J Dikeocha, Hannah R Wardill, Janet K Coller, et al.
Pharmacogenomics|June 24, 2014
Pharmacogenomics of methadone maintenance treatmentAndrew A Somogyi, Daniel T Barratt, Robert L Ali, et al.
Cancers|September 9, 2023
The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse EffectsAmanda S Maddern, Janet K Coller, Joanne M Bowen, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2018
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapySamantha K Korver, Rachel J Gibson, Joanne M Bowen, et al.
Inflammation|July 22, 2022
Investigation of TLR4 Antagonists for Prevention of Intestinal InflammationJanine S Y Tam, Janet K Coller, Clive A Prestidge, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Pharmacology & Therapeutics|February 10, 2012
Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependenceJanet K Coller, Mark R Hutchinson
European Journal of Clinical Pharmacology|October 30, 2008
Role of active metabolites in the use of opioidsJanet K Coller, Lona L Christrup, Andrew A Somogyi
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|April 4, 2006
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatmentsDaniel T Barratt, Janet K Coller, Andrew A Somogyi
Clinical Pharmacology and Therapeutics|March 7, 2007
Pharmacogenetics of opioidsAndrew A Somogyi, Daniel T Barratt, Janet K Coller
Journal of Cellular Physiology|July 31, 2020
Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory diseaseElise E Bruning, Janet K Coller, Hannah R Wardill, et al.
Clinical Nutrition ESPEN|July 17, 2024
Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical dataIfeoma J Dikeocha, Hannah R Wardill, Janet K Coller, et al.
Pharmacogenomics|June 24, 2014
Pharmacogenomics of methadone maintenance treatmentAndrew A Somogyi, Daniel T Barratt, Robert L Ali, et al.
Cancers|September 9, 2023
The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse EffectsAmanda S Maddern, Janet K Coller, Joanne M Bowen, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2018
Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapySamantha K Korver, Rachel J Gibson, Joanne M Bowen, et al.
Inflammation|July 22, 2022
Investigation of TLR4 Antagonists for Prevention of Intestinal InflammationJanine S Y Tam, Janet K Coller, Clive A Prestidge, et al.
Pageof 7